No data available
No data available
No data available
Camrex Consultants offer Expert Commercial Support for Life Science companies. We provide fractional or project-based marketing, product management and business development services. When you hire Camrex Consultants, you purchase PhD-level scientific knowledge combined with real-world experience gained from a range of senior commercial roles and 5 years of independent consulting.
Cancer Research Horizons is the innovation engine of Cancer Research UK – the world’s largest charitable funder of cancer research. We bring together the best minds, bold ideas, and the right partners to bridge the gap between academic research and taking drugs to market. We focus on the tougher, more profound ideas that can lead to true innovation, translating them into effective treatments and diagnostics for cancer patients.
To date we’ve played an instrumental role in forming over 70 startup companies. We’ve helped bring 11 cancer drugs to market, borne out of Cancer Research UK’s pioneering research. Through these drugs, we have enabled in excess of 6 million courses of treatment for cancer patients worldwide.
With access to Cancer Research UK’s network of 4,000 exceptional researchers, and over £400m of annual research spend, we’re a powerful partner in the fight to conquer cancer. By uniting our commercial partnerships and therapeutic innovation capabilities, Cancer Research Horizons is uniquely placed to support translational funding, entrepreneurial development, licensing and collaboration, start-up creation, and offer a full spectrum of drug discovery and clinical capabilities.
Every penny we make goes back into funding the next bold steps, to help bring forward the day when all cancers and conquered.
To date we’ve played an instrumental role in forming over 70 startup companies. We’ve helped bring 11 cancer drugs to market, borne out of Cancer Research UK’s pioneering research. Through these drugs, we have enabled in excess of 6 million courses of treatment for cancer patients worldwide.
With access to Cancer Research UK’s network of 4,000 exceptional researchers, and over £400m of annual research spend, we’re a powerful partner in the fight to conquer cancer. By uniting our commercial partnerships and therapeutic innovation capabilities, Cancer Research Horizons is uniquely placed to support translational funding, entrepreneurial development, licensing and collaboration, start-up creation, and offer a full spectrum of drug discovery and clinical capabilities.
Every penny we make goes back into funding the next bold steps, to help bring forward the day when all cancers and conquered.
Cancer Research Technology (CRT) is dedicated to advancing discoveries to beat cancer. We develop and commercialise exciting new discoveries in cancer research, working closely with leading clinical and academic institutions, pharmaceutical companies and biotechs worldwide. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. . . CRT is owned by Cancer Research UK, the world’s largest charitable funder of cancer research and we’re uniquely placed to capitalise on the research and connections of our parent organisation.
Carocell Bio are developing novel peptides to more safely and effectively treat inflammatory diseases.
Catalent, Inc. is a global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians.
Point of contact:
Peter F. Farmer, Senior Account Director
[email protected]
Linkedin: https://www.linkedin.com/in/peter-farmer-62843513/
Point of contact:
Peter F. Farmer, Senior Account Director
[email protected]
Linkedin: https://www.linkedin.com/in/peter-farmer-62843513/
As a global Contract Research Organization Laboratory (CRO) to the biopharmaceutical industry, CellCarta provides access to a broad offering of biomarker platforms and services. We partner with you to address the most complex scientific testing needs, delivering customized biomarker testing solutions to further the limitless potential of precision medicine.
With a foundation rooted in biomarker science, CellCarta has evolved into a leading global CRO offering services across immune monitoring, histopathology, proteomics, genomics, and sample logistics. Our integrated clinical laboratory network is trusted by sponsors worldwide to deliver customized assay development and regulatory-compliant trial support.
At CellCarta, we are committed to staying at the forefront of scientific advancements, continually integrating the latest innovations into our service offerings.
Our adaptive approach ensures that we remain a trusted partner, ready to meet the evolving challenges of precision medicine with cutting-edge solutions.
With a foundation rooted in biomarker science, CellCarta has evolved into a leading global CRO offering services across immune monitoring, histopathology, proteomics, genomics, and sample logistics. Our integrated clinical laboratory network is trusted by sponsors worldwide to deliver customized assay development and regulatory-compliant trial support.
At CellCarta, we are committed to staying at the forefront of scientific advancements, continually integrating the latest innovations into our service offerings.
Our adaptive approach ensures that we remain a trusted partner, ready to meet the evolving challenges of precision medicine with cutting-edge solutions.
Cellestial Health is a preclinical pharmaceutical development company which spun out from the University of Cambridge. Our small molecule therapeutics stabilise networks of brain cells called astrocytes to slow down or stop the progression of Parkinson's - the fastest-growing neurological disorder globally. Further, there is a strong scope for expansion to other conditions of the brain.